The mTOR (mammalian target of rapamycin) inhibitor rapamycin caused growth arrest in both androgendependent and androgen-independent prostate cancer cells; however, long-term treatment induced resistance to the drug. The aim of this study was to investigate methods that can overcome this resistance. Here, we show that rapamycin treatment stimulated androgen receptor (AR) transcriptional activity, whereas suppression of AR activity with the antiandrogen bicalutamide sensitized androgen-dependent, as well as AR-sensitive androgenindependent prostate cancer cells, to growth inhibition by rapamycin. Further, the combination of rapamycin and bicalutamide, but not the individual drugs, induced significant levels of apoptosis in prostate cancer cells. The net effect of rapamycin is determined by its individual effects on the mTOR complexes mTORC1 (mTOR/ raptor/GbL) and mTORC2 (mTOR/rictor/sin1/GbL). Inhibition of both mTORC1 and mTORC2 by rapamycin-induced apoptosis, whereas rapamycin-stimulation of AR transcriptional activity resulted from the inhibition of mTORC1, but not mTORC2. The effect of rapamycin on AR transcriptional activity was mediated by the phosphorylation of the serine/threonine kinase Akt, which also partially mediated apoptosis induced by rapamycin and bicalutamide. These results indicate the presence of two parallel cell-survival pathways in prostate cancer cells: a strong Akt-independent, but rapamycin-sensitive pathway downstream of mTORC1, and an AR-dependent pathway downstream of mTORC2 and Akt, that is stimulated by mTORC1 inhibition. Thus, the combination of rapamycin and bicalutamide induce apoptosis in prostate cancer cells by simultaneously inhibiting both pathways and hence would be of therapeutic value in prostate cancer treatment.
Introduction
Prostate cancer is monitored by serum levels of prostatespecific antigen (PSA), which is regulated by the androgen receptor (AR). It is estimated that following radical prostatectomy or radiation therapy as primary treatment, evidence of rising PSA values is observed in approximately 15-30% of patients and relates to recurrent prostate cancer, which is treated by androgen withdrawal therapy (Edwards and Bartlett, 2005) . Patients respond initially to such treatment but frequently relapse, indicative of the development of androgen-independent prostate cancer (AIPC) (Petrylak, 2005) . Currently, the only effective treatment for patients with AIPC is the chemotherapeutic agent docetaxel, which caused a small (o2.5 months), although significant, improvement in patient survival, compared with best standard of care (Boehmer et al., 2005; Petrylak, 2005) . Studies have shown that hormonal therapy does not cause cell death, but rather results in cell cycle arrest, whereas the development of androgen independence triggers a release from that arrest, and cell cycle progression, even in the absence of androgens (Agus et al., 1999) . Hence, the overall aim of this study is to identify agents that would prevent survival in AIPC cells, and to elucidate the molecular mechanisms involved.
The drug rapamycin is widely used as an immunosuppressant in renal and hepatic transplants, and is also used in clinical trials for various types of cancers (Lee et al., 2007) . We and others showed that rapamycin was effective in inhibiting the growth of both androgendependent and -independent prostate cancer cells (Ghosh et al., 2005; Wu et al., 2005) , and hence was promising as a new drug for the treatment of AIPC. However, in a phase I/II clinical trial, rapamycin as monotherapy was associated with tumor regression in only 25% of patients (Sharef et al., 2006) . Despite this, rising evidence points to the mTOR (mammalian target of rapamycin) pathway as a major regulator of prostate epithelial cell growth and death, cell motility and angiogenesis (Gao et al., 2003; Cinar et al., 2005; Ghosh et al., 2005; Wu et al., 2005; Cao et al., 2006; Kremer et al., 2006) . This warranted further investigation of rapamycin as an antineoplastic agent in combination studies. Here, we examined the cause for the failure of rapamycin as monotherapy and means to overcome resistance to this therapy.
To identify the mechanism by which prostate cancer cells develop resistance to rapamycin following longterm treatment, we investigated the effect of this drug on downstream targets. The only known target of rapamycin is mTOR. mTOR is activated downstream of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, a major regulator of cell survival in mammalian cells. Activated mTOR forms two distinct multiprotein complexes: mTORC1 consisting of mTOR, raptor and GbL (also known as mLST8), and mTORC2 consisting of mTOR, rictor, sin1 and GbL (Sarbassov et al., 2005a) . Our data show that rapamycin inhibits both mTORC1 and mTORC2 in prostate cancer cells. Rapamycin complexes with the immunophillin FK506-binding protein (FKBP12) (Sabatini et al., 1994) , and the rapamycin/FKBP12 complex can bind mTORC1 but not mTORC2 (Jacinto et al., 2004; Sarbassov et al., 2004) . Hence, until recently it was thought that mTORC2 is rapamycin insensitive. However, rapamycin/FKBP12 can also bind to free mTOR (Brown et al., 1994) , and it has been postulated that this inhibits de novo production of mTORC2 (Sarbassov et al., 2006) . mTORC1 regulates the phosphorylation of downstream targets p70S6 kinase and 4E-BP1, which regulate translation initiation (Gingras et al., 2001) . On the other hand, mTORC2 has been shown to regulate Akt phosphorylation (Hresko and Mueckler, 2005; Sarbassov et al., 2005b) . Thus Akt both regulates, and is regulated by mTOR.
In this paper, we show that rapamycin treatment stimulated AR transcriptional activity, whereas suppression of AR activity with the antiandrogen bicalutamide sensitized androgen-dependent, as well as AR-sensitive androgen-independent prostate cancer cells, to growth inhibition by rapamycin. Rapamycin treatment inhibited both mTORC1 and mTORC2, and inhibition of both complexes induced apoptosis, whereas rapamycin-induced AR transcriptional activity resulted from the inhibition of mTORC1, but not mTORC2. Our results indicate the presence of two parallel cell-survival pathways in prostate cancer cells: a strong Aktindependent, but rapamycin-sensitive, pathway downstream of mTORC1, and an AR-dependent pathway downstream of mTORC2 and Akt, which is stimulated by mTORC1 inhibition. Simultaneous inhibition of both pathways by the combination of rapamycin and bicalutamide induce apoptosis in prostate cancer cells and hence would be of therapeutic value in prostate cancer treatment.
Results
Rapamycin inhibits prostate cancer cell growth but stimulates AR transcriptional activity To evaluate the effect of rapamycin on prostate cancer cell growth, we treated AR-positive LNCaP ( Figure 1a ) and AR-negative PC-3 cells (Figure 1b ) with 1 and 100 nM rapamycin. Both doses of rapamycin were effective in inhibiting cell growth in these cell lines (Figures 1a and b) , although the effect of rapamycin in LNCaP cells (42% inhibition on day 5 with 1 nM rapamycin, Po0.001) was less compared to that in PC-3 cells (73% inhibition on day 5 with 1 nM rapamycin, Po0.0001). As the physiological level of rapamycin achieved in patients is of the order of 1 nM (Sharef et al., 2006) , all further studies, unless specified, were conducted at this concentration. Previous studies showed that rapamycin increased PSA levels in LNCaP cells (Cinar et al., 2005) . However, the mechanism by which rapamycin stimulates PSA was not known. Here we show that in LNCaP cells and its AI sublines C4-2 and LNAI, rapamycin stimulated AR transcriptional activity on a human PSA promoter tagged to a luciferase construct (hPSA-luc) approximately 2-to 2.5-fold (Po0.001) (Figure 1c ). These studies indicate that rapamycin is a good inhibitor of both AR-positive as well as AR-negative prostate cancer cells, but in the AR-positive cells, rapamycin also induced AR transcriptional activity.
Rapamycin-induced AR transcriptional activity promotes growth of prostate cancer cells As rapamycin has a greater effect on AR-negative cells compared to their AR-positive counterparts, we examined whether the AR affected the response of these cells to the growth inhibitory effects of rapamycin. The AR is a transcription factor and promotes the transcription of many genes, including PSA, by binding to the androgenresponse element in their promoter region. The AR has also been shown to regulate proliferation and survival in androgen-dependent prostate epithelial cells (see Supplementary Information), but the exact targets of AR in the cell cycle and survival machinery, other than p21
Cip1/Waf1 (Lu et al., 1999) , are not known. Studies show that low levels of AR stimulation (represented by three-to fourfold increase in PSA) increased proliferation rates in prostate cancer cells, whereas high levels of stimulation (>15-fold) were inhibitory (Supplementary Information). These results indicate that although PSA itself is not a regulator of cell growth, its expression is an indicator of AR transcriptional activity on other target genes as well.
Rapamycin induced a twofold (100%) increase in AR transcriptional activity in both LNCaP and C4-2 cells (Figure 2a ). This increase was within the stimulatory range of the effect of AR activity on cell proliferation (Supplementary Information). On the other hand, bicalutamide, a competitive inhibitor of AR ligand binding, inhibited not only basal levels of AR transcriptional activity, but also AR transcriptional activity stimulated by rapamycin (Figure 2a) , resulting in suppression of rapamycin-induced PSA expression (Figure 2b , upper panel). However, bicalutamide was unable to prevent rapamycin-induced increase in AR expression (Figure 2b , second panel), and had no effect on rapamycin inhibition of p70S6 kinase phosphorylation ( Figure 2b , third panel). These results indicate that bicalutamide prevented rapamycin-induced AR transcriptional activity without affecting rapamycin's effect on downstream targets of mTOR.
If rapamycin-induced AR activity increased transcription of target genes resulting in increased cell growth, then inhibition of this activity by bicalutamide treatment should prevent growth. To test this hypothesis, we treated LNCaP and C4-2 cells with 1 nM rapamycin, 10 mM bicalutamide or a combination of the two. Rapamycin inhibited cell growth significantly compared to vehicle in both LNCaP (54.86%, P ¼ 0.001) (Figure 2c ) and C4-2 (45.37%, Po0.001) cells (Figure 2d ). In contrast, bicalutamide inhibited cell growth in androgen-dependent LNCaP (48.64%, P ¼ 0.001) but not in androgen-independent C4-2 cells (À6.018%, P ¼ 0.198) (Figures 2c and d) . Despite this, bicalutamide sensitized both cell lines to the effects of rapamycin (Figures 2c and d) , (69.43% decrease in LNCaP cells, P ¼ 0.001; 63.13% in C4-2 cells, Po0.001). However, this effect was not seen in ARnull PC-3 cells (not shown), indicating that this effect needed the presence of the AR. Our results indicate that rapamycin-induced AR transcriptional activity induced proliferation and prevented complete growth inhibition by rapamycin, whereas bicalutamide reversed this effect by inhibiting rapamycin-induced AR transcriptional activity. Thus, rapamycin induction of AR transcriptional activity that results in increased cell growth is a likely cause for the resistance that prostate cancer cells develop to long-term rapamycin treatment. 
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Rapamycin and bicalutamide in combination induces apoptosis in prostate cancer cells We further investigated the effect of the combination of rapamycin and bicalutamide in AI sublines of LNCaP cells. As growth inhibition can be caused by decreased cell proliferation or by increased apoptosis, we investigated the effect of this combination of drugs on both factors. Following 2 days of treatment, rapamycin, but not bicalutamide, resulted in decreased S-phase in androgen-independent LNAI cells (31.33% with rapamycin, P ¼ 0.0028 vs 8.22% with bicalutamide, P ¼ 0.088) without significantly affecting G2/M phase or apoptosis as determined by flow cytometry (Figure 3a ). The combination of bicalutamide and rapamycin caused further decrease in S-phase (39.5%, P ¼ 0.00099) ( Figure 3a ) and a substantial increase in the number of cells undergoing apoptosis (4.18-fold increase, P ¼ 0.029) (Figure 3a) . Similar results were obtained with C4-2 cells (not shown). Thus, the combination of bicalutamide and rapamycin caused the onset of apoptosis, which explains the decreased growth by the combination treatment.
The long-term effect of rapamycin treatment was estimated by clonogenic assay. LNAI cells were cultured in the presence of vehicle (dimethylsulfoxide (DMSO)) or 1 nM rapamycin for 14 days. Although bicalutamide as a single agent failed to inhibit growth in this cell line (21% increase, P ¼ 0.121), rapamycin as a single agent had a partial effect (42.69% reduction, P ¼ 0.0005) (Figure 3b ). However, rapamycin and bicalutamide, in combination, resulted in almost complete inhibition of clone formation (87.72% reduction, P ¼ 0.00018) (Figure 3b ). These results are consistent with the induction of apoptosis by the rapamycin-bicalutamide combination, as indicated by the onset of PARP cleavage in both LNCaP and C4-2 cells treated with Apoptosis induced by the rapamycin-bicalutamide combination is mediated by the inhibition of both mTORC1 and mTORC2 Next, we investigated the mechanism by which the combination of rapamycin and bicalutamide induced large levels of apoptosis in androgen-dependent as well as androgen-independent prostate cancer cells despite neither drug alone having a similar effect. The mTOR complexes mTORC1 (mTOR/raptor) and mTORC2 (mTOR/rictor) have, to the best of our knowledge, never been compared in prostate cancer. We investigated whether rapamycin induction of AR activity was mediated by the inhibition of these complexes. Rapamycin treatment did not significantly affect the expression of raptor (Figure 4a, upper panel) , but severely impeded the activation of mTORC1 as indicated by the inability of the mTORC1 target p70S6 kinase to activate its substrate, the ribosomal protein S6 (Figure 4a , second panel). This drug also decreased rictor expression at X1 nM (Figure 4a , third panel), but not the expression of total Akt (Figure 4a, lowermost panel) . Thus, rapamycin inhibited both mTORC1 (mTOR/ raptor) and mTORC2 (mTOR/rictor), albeit by two different mechanisms.
As rapamycin inhibited both these complexes, the effect of the combination of rapamycin and bicalutamide on apoptosis could be mediated by mTORC1, mTORC2 or both. To determine the function of these complexes on apoptosis, we inhibited the expression of raptor or rictor using small interfering RNA (siRNA) to both these proteins. Inhibition of both raptor and rictor induced apoptosis in C4-2 cells, although the inhibition of mTORC1 had a greater effect compared to the inhibition of mTORC2 (Figure 4b ). Significantly, further treatment with bicalutamide enhanced the effect of raptor inhibition but not rictor inhibition. On the other hand, overexpression of both raptor and rictor inhibited apoptosis induced by the combination of rapamycin and bicalutamide (Figure 4c ), but again, the effect of raptor overexpression was more significant than that of rictor overexpression. These results indicate that the effect of rapamycin on apoptosis is mediated by the inhibition of both mTORC1 and mTORC2.
Rapamycin-induced AR transcriptional activity is caused by inhibition of mTORC1, but not mTORC2
We next investigated the effect of these proteins on rapamycin-induced AR transcriptional activity. As Akt is a regulator of survival in prostate cancer cells, we also investigated the effects of mTORC1 and mTORC2 on Akt phosphorylation. Depletion of raptor levels stimulated Akt phosphorylation (Figure 5a ), whereas increased expression of raptor prevented rapamycininduction of Akt phosphorylation in these cells (Figure 5b) . Similarly, raptor siRNA stimulated AR transcriptional activity 74.4%, which is consistent with the effect of rapamycin (80.6% increase over control) (Figure 5c ), whereas overexpression of raptor prevented rapamycin stimulation of AR transcriptional activity (Figure 5d ). In contrast, rictor had the opposite effectinhibition of rictor prevented rapamycin-induced Akt phosphorylation ( Figure 6a ) and AR transcriptional activity on hPSA-luc (Figure 6c ), whereas overexpression of rictor stimulated Akt phosphorylation (Figure 6b ) as well as AR transcriptional activity (Figure 6d ). Thus, mTORC1 inhibited whereas mTORC2 stimulated AR activity and Akt phosphorylation.
Rapamycin's effect on AR transcriptional activity is mediated by Akt phosphorylation Next, we investigated the mechanism by which rapamycin induced AR transcriptional activity. Rapamycininduced AR transcriptional activity on hPSA-luc was inhibited by Akt siRNA in C4-2 cells, whereas basal individually on apoptosis. C4-2 cells were transfected with a control small interfering RNA (siRNA) or with raptor or rictor siRNA, and then treated with dimethylsulfoxide (DMSO) (vehicle) or 10 mM bicalutamide. Cells were collected after 48 h and analysed for percent of apoptotic cells by flow cytometry. (c) Effect of overexpression of raptor or rictor on apoptosis induced by rapamycin þ bicalutamide. C4-2 cells were transfected with vector (pCMV) or with myc-raptor or myc-rictor, then treated with DMSO, 10 mM bicalutamide, 1 nM rapamycin or both. Apoptosis was analysed as described above.
Androgen receptor regulation by rapamycin Y Wang et al levels were minimally affected (Figure 7a ). Further, transfection of a constitutively active form of Akt (pCMV-6-myr-Akt-HA), but not a control vector (pCMV-HA), promoted AR transcriptional activity both in vehicle-and rapamycin-treated cells (Figure 7b ). Also, a dominant negative Akt mutant (pCMV-6-Akt-K179M) prevented this effect (not shown). The plasmids were kindly provided by Dr Thomas F Franke, Columbia University, NY, and were described by us elsewhere (Ghosh et al., 2005) . Akt has been shown to both stimulate and inhibit AR activity under different conditions (Lin et al., 2003) ; in this case, Akt has a stimulatory effect on the AR. These results demonstrate that the effects of rapamycin on AR transcriptional activity are mediated by Akt phosphorylation.
Rapamycin's effect on apoptosis is only partially mediated by Akt However, constitutive expression of Akt only partially inhibited apoptosis induced by combination treatment with rapamycin and bicalutamide (Figure 7c ), and is likely the effect of inhibition of mTORC2 but not mTORC1. Hence, Akt phosphorylation mediates the effects of rapamycin on AR transcriptional activity but only partially mediates the effect of rapamycin on apoptosis. These results indicate the presence of a strong Akt-independent cell-survival pathway mediated by mTORC1. Thus, mTORC1 and the AR activate parallel cell-survival pathways. Therefore, simultaneous inhibition of both pathways by rapamycin and bicalutamide induce apoptosis in prostate cancer cells.
Discussion
The aim of this paper was to determine the reason why prostate cancer cells developed resistance to rapamycin following long-term treatment with the drug and to design methods of overcoming this resistance. The effect of increasing AR transcriptional activity on cell proliferation is biphasic: whereas low levels stimulated proliferation, high levels inhibited it (see Supplementary Information). Our data showed that treatment with 1 nM rapamycin induced a twofold increase in AR Androgen receptor regulation by rapamycin Y Wang et al transcriptional activity, which was in the range that stimulated cell proliferation. This effect diminished the growth-inhibitory effects of rapamycin, resulting in resistance to rapamycin. Simultaneous treatment with rapamycin and bicalutamide, an inhibitor of AR transcriptional activity, sensitized the cells to rapamycin-induced growth inhibition and was able to overcome this resistance.
Our results indicate that the combination of rapamycin and bicalutamide, but not the individual drugs, induced significant apoptosis in prostate cancer cells. Rapamycin as monotherapy was unable to induce longterm growth inhibition because of the activation of an AR-dependent cell-survival pathway. On the other hand, bicalutamide alone was unable to inhibit cell growth because of the presence of a strong Akt-independent survival pathway downstream of mTORC1. Thus, mTOR kinase activity and AR transcriptional activity regulate survival in prostate cancer cells by parallel signaling pathways. When either pathway is inhibited, cell survival is regulated by the other one. Hence, apoptosis was induced only when both pathways were simultaneously inhibited, (schematically represented in Figure 8 ).
These data demonstrate that rapamycin inhibits both mTORC1 and mTORC2 in prostate cancer cells. Inhibition of mTORC1 induced apoptosis but also resulted in stimulation of AR transcriptional activity. mTORC1 phosphorylates downstream targets p70S6 kinase and 4E-BP1. Previous studies have shown that inhibition of p70S6 kinase stimulated Akt phosphorylation (Shi et al., 2005; Tzatsos and Kandror, 2006) , whereas mTORC1's effects on cell survival are likely mediated by translation initiation. On the other hand, inhibition of mTORC2 inhibited both cell survival as well as AR transcriptional activity. The latter effects are likely mediated by Akt phosphorylation. Previous studies had shown that Akt is phosphorylated by mTORC2 at Ser 473 (Sarbassov et al., 2004 (Sarbassov et al., , 2005b (Sarbassov et al., , 2006 . However, Akt phosphorylation persisted even in cells treated with rictor siRNA (Figure 6a ). This suggests that very little rictor is needed for Akt phosphorylation in prostate cancer cells. It is likely that AIPC cells have evolved to develop alternate pathways of Akt (Ser473) phosphorylation, as suggested by other studies (Persad et al., 2001) .
The overall effect of rapamycin in these cells, therefore, is the stimulation of Akt phosphorylation. It may Androgen receptor regulation by rapamycin Y Wang et al be noted that even in PTEN-negative cells such as LNCaP and its AI sublines, pAkt is not at saturation levels. PI3K is the enzyme catalysing the conversion of PIP2 to PIP3, whereas PTEN is a phosphatase that converts PIP3 back to PIP2. PIP3 then phosphorylates PDK1, which in turn phosphorylates Akt at Thr 308. This stimulates phosphorylation at Ser 473. In the absence of PTEN, PI3K constitutively converts PIP2 to PIP3, which increases the basal level of Akt phosphorylation, but does not result in constitutive activation of Akt. Hence, even in PTEN-negative cells, further stimulation with rapamycin results in additional phosphorylation of Akt. We show that the effect of rapamycin on AR transcriptional activity is mediated by the increase in Akt phosphorylation. Notably, Akt has been shown to both stimulate and inhibit AR activity under different conditions (Lin et al., 2003) ; in this case, Akt has a stimulatory effect on the AR. Significantly, this data show that rapamycin-induced AR transcriptional activity is ligand-dependent. Inhibition of ligand binding by bicalutamide prevented rapamycin's effect on AR transcriptional activity.
In conclusion, in this study, we provide novel evidence that bicalutamide alone was unable to inhibit cell growth and induce apoptosis in AIPC cells, because of the presence of a strong androgen-independent, but rapamycin-sensitive, survival pathway downstream of mTOR. On the other hand, rapamycin as monotherapy was unable to induce long-term growth inhibition because of the stimulation of an AR-dependent cellsurvival pathway by rapamycin treatment. Rapamycin's effects are mediated by the inhibition of both mTORC1 and mTORC2-inhibition of mTORC1 stimulated AR transcriptional activity, but induced apoptosis in prostate cancer cells by an AR-independent mechanism; whereas rapamycin inhibition of mTORC2 inhibited AR transcriptional activity and also induced apoptosis by an AR-dependent mechanism. Thus, the mTORC1 and AR pathways regulate survival in prostate cancer cells in parallel, and apoptosis was induced only when both pathways were simultaneously inhibited with rapamycin and the antiandrogen bicalutamide. These results explain why a combination of rapamycin and bicalutamide would be of therapeutic value in prostate cancer treatment.
Materials and methods

Cell culture and pharmacological treatments
The LNCaP cells were purchased from American Type Culture Collection, Manassas, VA, USA, whereas C4-2 cells were from UroCor, (Oklahoma City, OK, USA). Androgen-independent clones of LNCaP cells (LNAI cells) were obtained by prolonged culture of LNCaP cells in 'androgen-free medium': phenol red-free RPMI 1640 with 5% charcoal-stripped fetal bovine serum (CSS, Hyclone, Logan, UT, USA). All other cells were cultured in 'complete-medium': RPMI 1640 medium with 5% fetal bovine serum (Invitrogen, Grand Island, NY, USA) unless otherwise specified. Bicalutamide (Casodex) was obtained from AstraZeneca, Cheshire, UK. Rapamycin was obtained from Calbiochem, EMD Biosciences, San Diego, CA, USA.
Transfections and plasmids
Cells were transiently transfected using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's specifications based on the established protocols using 2 mg plasmid DNA as described earlier (Ghosh et al., 1999 (Ghosh et al., , 2005 . A human PSA reporter plasmid consisting of the human PSA 5 0 -flanking region (À631/À1) containing androgen-response elements I and II tagged to a luciferase construct (hPSA-luc) was kindly provided by Dr Bandana Chatterjee, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 
RNA inhibition
Flow cytometry
The fraction of cells in S-phase was determined by flow cytometry in propidium iodide-stained ethanol-fixed cells as described previously (Ghosh et al., 2002) , whereas the fraction of cells undergoing apoptosis was calculated as the percentage of cells appearing as a sub-G1 peak. Cells in early apoptosis were calculated as Annexin V-stained cells following 15 min of dual staining by Annexin V-FITC and propidium iodide in Data were collected on 20 000 cells as determined by forward and right angle light scatter and stored as frequency histograms; data used for cell cycle analysis was further analysed using MODFIT (Verity software, Topsham, ME, USA).
MTT assay
Cells were plated in 24-well plates and treated as indicated. Following treatment, each well was incubated with 15 ml of 5 mg/ml 3-[4,5-Dimethylthiazol-2yl]-2,5-diphenyl-tetrazolium bromide (MTT) for 1 h in a CO 2 incubator at 37 1C. The medium was aspirated and 0.5 ml DMSO was added per well. Formazan intensity was estimated at 560 nm.
Clonogenic assay Cell survival after treatment with rapamycin and/or bicalutamide alone or in combination was measured by clonogenic assay. Single-cell suspensions of 6000 cells were seeded into 60-mm culture dishes on day 0 and allowed to attach for 24 h at 37 1C in media containing 5% fetal bovine serum. The cells were then treated with rapamycin (1 nM), bicalutamide (10 mM) or a combination of the two. Control cells were treated with equivalent volume DMSO (vehicle for both drugs). Drugs were washed out 24 h post-treatment and fresh 5% fetal bovine serum media were added. After 14 days, colonies were fixed in fixing solution (33.3% acetic acid and 66.7% methanol) for 15 min at room temperature and stained with 1.0% crystal violet. Dishes were washed with water and visible colonies containing approximately 50 or more cells were counted.
Western blotting and immunoprecipitation
These techniques were performed as described elsewhere (Ghosh et al., 2001 (Ghosh et al., , 2002 
AR transcriptional activity
Reporter gene activity was determined by luciferase assay (Hartig et al., 2002) . Cells were co-transfected with 2 mg of hPSA-luc with 2 mg of pCMV-bGal using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. Cells grown in complete medium for 24 h were treated as required for an additional 48 h. After 48 h, cells lysate were prepared for performing luciferase assays using a luciferase enzyme assay system (Promega Corp., Madison, WI, USA). Each transfection experiment was performed in triplicate on at least three separate occasions. Results represent an average of independent experiments with data presented as relative luciferase activity using means of untreated controls as standards.
